Results for this period
First quarter1 June 2026 to 31 August 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Sales of detergents, solid fuels, and infection-control products remained firm. In the Chemical Business, cross-selling, expansion of high-value-added products, increased product volumes, and price revisions contributed to higher revenue and profit, while higher raw material, personnel, and logistics costs were factors behind the decline in profit. In the Healthcare Business, lower overseas and domestic sales led to declines in revenue and profit.
Not applicable (no matters to report in the notes on the going concern assumption)
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2026 to 31 August 2026 |
| Net Sales | ¥6,334 million (YoY +5.5%) |
| Operating profit | ¥585 million (YoY +0.5%) |
| Ordinary income | ¥608 million (YoY -1.2%) |
| Profit attributable to owners of the parent | ¥415 million (YoY -0.8%) |
| Net income per share | ¥71.00 |
| Equity ratio | End of the current fiscal period 70 / End of previous period 68.2 |
| Total assets | ¥23,181 million |
| Net assets | ¥16,219 million |
| Full-year earnings forecast | Net Sales ¥27,500 million (YoY +11.7%) / Operating profit ¥1,800 million (YoY -15.0%) / Ordinary income ¥1,850 million (YoY -16.6%) / Profit attributable to owners of the parent ¥1,285 million (YoY -32.4%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥77 → ¥84（+9.1%） |
| Segment revenue | Chemicals Business ¥6,156 million (YoY +9.1%), Healthcare Business ¥177 million (YoY -51.2%) |
| Segment profit | Chemicals Business ¥574 million (YoY +22.7%), Healthcare Business ¥10 million (YoY -90.8%) |
| Depreciation and amortization | ¥129,054 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on disposal and sale of non-current assets ¥9 thousand |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 5,943,052 Shares |
| Treasury Shares at Period-End | 148,306 Shares |
| Factors Behind Changes in Business Performance | Sales of detergents, solid fuels, and infection-control products remained firm. In the Chemical Business, cross-selling, expansion of high-value-added products, increased product volumes, and price revisions contributed to higher revenue and profit, while higher raw material, personnel, and logistics costs were factors behind the decline in profit. In the Healthcare Business, lower overseas and domestic sales led to declines in revenue and profit. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as sales of detergents, solid fuels, and infection-control products remained firm. On the earnings side, the impact of lower profit in the Healthcare Business and higher raw material costs in the Chemical Business was absorbed through sales growth and price revisions in the Chemical Business.